- Conditions
- Obesity and Obesity-related Medical Conditions
- Interventions
- Bariatric Surgery, Semaglutide, Tirzepatide
- Procedure · Drug
- Lead sponsor
- Ali Aminian
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 177
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- Surveys, Indirect Calorimetry, Body composition, Anthropometrics
- Behavioral · Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Needham, Massachusetts
- Conditions
- Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Weight Management
- Interventions
- ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Type 2 Diabetes
- Interventions
- HM11260C, liraglutide, Placebo
- Drug
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- CA, California
- Conditions
- Facial Skin Aging, Facial Volume Loss, Wrinkle Appearance
- Interventions
- GLP-1 Receptor Agonists
- Drug
- Lead sponsor
- Ponsky Facial Aesthetics And Plastic Surgery, Llc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Beachwood, Ohio
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Spinal Cord Injuries, Insulin Resistance, Pre Diabetes, Obesity
- Interventions
- Semaglutide 1MG Injection [Ozempic], No Intervention
- Drug · Other
- Lead sponsor
- James J. Peters Veterans Affairs Medical Center
- Federal
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- West Orange, New Jersey
- Conditions
- Obesity, Overweight, or Chronic Weight Management
- Interventions
- aleniglipron or placebo
- Drug
- Lead sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Chicago, Illinois • Richfield, Minnesota + 8 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 28
- States / cities
- Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
- Conditions
- Alcohol Use Disorder (AUD)
- Interventions
- Pemvidutide, Placebo
- Drug · Other
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 9 more
- Conditions
- Diabetes Mellitus
- Interventions
- Albiglutide 30 mg, Albiglutide 50 mg, Albiglutide matching placebo
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 9,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 146
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 125 more
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Interventions
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program
- Procedure · Drug · Behavioral
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Muscle Loss, Obesity
- Interventions
- Enobosarm, Semaglutide
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 14
- States / cities
- Anniston, Alabama • Cullman, Alabama • San Diego, California + 11 more
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Sarcopenia, Obesity, Muscle Loss, Older Adults
- Interventions
- Calcium-HMB Plus Vitamin D3, Matching placebo
- Dietary Supplement · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders, Chemically-Induced Disorders, Mental Disorder, Opioid
- Interventions
- Semaglutide Pen Injector, Placebo
- Drug
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Fall River, Massachusetts • New York, New York + 1 more
- Conditions
- Type2 Diabetes, Kidney Diseases
- Interventions
- Exenatide Extended Release for Inj Susp 2 MG, Placebo
- Drug
- Lead sponsor
- University at Buffalo
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Diabetes
- Interventions
- Gut motility quantification using a capsule after initiating GLP-1RA therapy
- Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases
- Interventions
- Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 714,582 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 7
- States / cities
- Elizabeth, New Jersey • Hamilton, New Jersey • Livingston, New Jersey + 4 more
- Conditions
- Obesity & Overweight, Mobility Disability, HOMA-IR
- Interventions
- Enobosarm, Semaglutide (Wegovy) weekly injection
- Drug
- Lead sponsor
- Veru Inc.
- Industry
- Eligibility
- 65 Years to 100 Years
- Enrollment
- 239 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Doral, Florida • Miami, Florida + 7 more
- Conditions
- Diabetic Kidney Disease, Type 1 Diabetes
- Interventions
- Semaglutide, Placebo
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Seattle, Washington • Spokane, Washington
- Conditions
- Obesity
- Interventions
- BMF-650
- Drug
- Lead sponsor
- Biomea Fusion Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Obesity
- Interventions
- Saxenda, Placebos, RYGB
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota